Home › RedHill Biopharma - 9 Late Stage Clinical Assets, $150 Million Market Cap - Is It Undervalued?
 

Keywords :   


RedHill Biopharma - 9 Late Stage Clinical Assets, $150 Million Market Cap - Is It Undervalued?

2015-09-11 14:41:16| Biotech - Topix.net

Every market day, we select up to 20 of our authors' top long and short ideas, exclusively for PRO subscribers. RedHill focuses on late stage oral gastrointestinal drugs; the company has two potential blockbusters in Phase 3 studies, 9 active clinical programs in total.

Tags: is it market million

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
26.04Does history repeat itself?
26.04FDA finalizes guidance to provide further clarity on Veterinary Feed Directives
26.04Post Office paid widow in instalments for silence
26.04NCBA statement on USDA final traceability rule
26.04Kimberly-Clark, Amcor Develop 30% Recycled Content Packaging
26.04IST America showcasing new products at RadTech UV&EB Technology & Conference
26.04Organic Baby Shampoo Market Size to Grow by $148.4 Million in 2027
26.04Movistar Plus+ to create real-time short-form sports video with WSC Sports
More »